Short answer
TG THERAPEUTICS, INC. (TGTX) filed an 8-K current report with the SEC on May 27, 2026 reporting Item 8.01 (Other Events). Positive topline Phase 3 ENHANCE results support a consolidated single-infusion BRIUMVI initiation regimen.
TG THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Positive topline Phase 3 ENHANCE results support a consolidated single-infusion BRIUMVI initiation regimen
- BRIUMVI targets adults with relapsing multiple sclerosis, potentially improving treatment convenience and adoption
- Randomized, double-blind design strengthens evidentiary value for future regulatory and commercial decisions
- Full efficacy and safety results are in Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TG THERAPEUTICS, INC. 8-K filings
Get the next TGTX 8-K as it lands
Follow TGTX for push alerts, or ask the research agent what this filing means.